Featured

Novel engineered vectors (recombinant adeno-associated virus [vAAV]) may provide efficient targeting for photoreceptors avoiding risks of collateral damage.

Researchers at the Department of Ophthalmology, Ludwig-Maximilians-University, Munich, have reported results on novel engineered viral vectors aimed to efficiently target photoreceptors.  The research used a… Read More »Novel engineered vectors (recombinant adeno-associated virus [vAAV]) may provide efficient targeting for photoreceptors avoiding risks of collateral damage.

Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Ph.D.

Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Paperback ISBN: 9780128162224 eBook ISBN: 9780128167274; Pages 383,… Read More »Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Ph.D.

Editas Medicine Inc. (NASDAQ:EDIT), and Allergan plc (NYSE:AGN), progress option rights to develop CRISPR technology for treatment of LCA 10

Editas Medicine, Inc. (NASDAQ: EDIT), based in Dublin, Ireland and Cambridge, Massachusetts, and Allergan plc (NYSE: AGN), also headquartered in Dublin, Ireland have announced the… Read More »Editas Medicine Inc. (NASDAQ:EDIT), and Allergan plc (NYSE:AGN), progress option rights to develop CRISPR technology for treatment of LCA 10